Kirsten Lawson summarises a new ‘state of the art review’ in the BMJ which focuses on novel and emerging pharmacotherapy and neuromodulation for people with ‘treatment resistant depression’.
[read the full story...]Using the highs to combat the lows: ketamine-assisted therapy for anxiety and depression
In her debut blog, Gabrielle Williams reviews a US study on the safety and effectiveness of ketamine-assisted therapy (a digital intervention combining psychotherapy, journaling and ketamine) for moderate to severe anxiety and depression.
[read the full story...]Psilocybin for ‘treatment-resistant depression’: an island of hope in an ocean of uncertainty?
In this blog, UCL MSc students consider an RCT published in the New England Journal of Medicine, which suggests that psilocybin-assisted psychotherapy may help reduce depression in people with severe and enduring illness, but side effects are common and more research is needed to look into longer term effects.
[read the full story...]Psychedelics-assisted psychotherapy for alcohol use disorder: room for more evidence
In her debut blog, Heidi Stevens reviews a recent US randomised controlled trial on psilocybin-assisted psychotherapy for adults with alcohol use disorder, which leaves us with more questions than answers.
[read the full story...]Ketamine and suicidal ideation: French trial finds modest short-term effects
Anya Borissova reviews a French trial that claims to be evidence that “ketamine is rapid, safe in the short term, and has persistent benefits for acute care in suicidal patients”.
[read the full story...]How could MDMA-assisted and psilocybin-assisted psychotherapy help people with depression and PTSD?
Anya Borissova and Philip Brooks consider a recent review exploring MDMA-assisted psychotherapy and psilocybin-assisted psychotherapy for trauma-related mental health difficulties.
[read the full story...]Ketamine “shows promise” as an anti-suicidal ideation agent, but will this promise ever be realised?
Rosalind McAlpine and Karel Kieslich summarise a recent systematic review which focuses on the rapid anti-suicidal ideation effect of ketamine.
[read the full story...]Can ketamine metabolites and gamma power help predict clinical response for ‘treatment resistant depression’?
Anya Borissova summarises a recent randomised placebo-controlled trial that evaluated ketamine metabolites, clinical response, and gamma power for major depression.
[read the full story...]Turn on, or tune out? Is psilocybin assisted therapy close to becoming a first-line treatment for depression?
James Rucker and Sameer Jauhar summarise a recent RCT on the effectiveness of psilocybin assisted therapy versus escitalopram assisted therapy for major depressive disorder.
[read the full story...]Patients’ experience of ketamine treatment for depression: the ‘Ketamine and me’ project
In her debut blog, Harmony Jiang reviews a recent qualitative study exploring patients’ experience and response to ketamine treatment for depression.
[read the full story...]